Seagen Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$512.5M
Doctors Paid
15,720
Transactions
137,462
2024 Total
$52,326
Payment Breakdown by Category
Research$491.9M (96.0%)
Consulting$5.7M (1.1%)
Food & Beverage$1.9M (0.4%)
Travel$1.5M (0.3%)
Royalty/License$641,000 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $491.9M | 47,913 | 96.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9.0M | 2,977 | 1.7% |
| Consulting Fee | $5.7M | 2,104 | 1.1% |
| Food and Beverage | $1.9M | 72,862 | 0.4% |
| Travel and Lodging | $1.5M | 4,607 | 0.3% |
| Education | $1.0M | 6,773 | 0.2% |
| Royalty or License | $641,000 | 3 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $497,189 | 203 | 0.1% |
| Grant | $301,623 | 19 | 0.1% |
| Charitable Contribution | $1,100 | 1 | 0.0% |
Payments by Type
Research
$491.9M
47,913 transactions
General
$20.6M
89,549 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| The CompassHER2 Trials (COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib | $76.7M | 0 | 156 |
| Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer | $43.2M | 0 | 2,708 |
| Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | $43.0M | 0 | 7,661 |
| Pediatric classical hodgkin lymphoma consortium study: chod17 | $28.5M | 0 | 144 |
| A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer | $28.2M | 0 | 4,075 |
| A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) | $20.7M | 0 | 149 |
| A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | $16.2M | 0 | 816 |
| A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | $14.5M | 0 | 4,022 |
| Targeted Agent and Profiling Utilization Registry | $12.1M | 0 | 36 |
| A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) | $9.0M | 0 | 826 |
| Open-Label Phase 1 Study of SGN-B7H4V for Solid Tumors | $8.8M | 0 | 1,105 |
| A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment | $6.7M | 0 | 3,837 |
| A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer | $6.6M | 0 | 1,132 |
| A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma | $6.3M | 0 | 774 |
| A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma | $6.1M | 0 | 51 |
| Phase 1b/2 Open-label single arm study to evaluate safety and efficacy of tucatinib in combination with palbociclimb and letrozole in subjects with hormone receptor positive and HER2-positive metastatic breast cancer | $6.1M | 0 | 42 |
| A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) | $5.8M | 0 | 765 |
| A Phase 1 Study of SGN-B6A in Advanced Solid Tumors | $5.5M | 0 | 821 |
| PACIFIC: A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma | $5.5M | 0 | 15 |
| A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | $5.1M | 0 | 1,890 |
| A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer | $5.1M | 0 | 1,286 |
| A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) | $5.0M | 0 | 1,304 |
| A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) | $5.0M | 0 | 4 |
| Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer | $4.9M | 0 | 1,266 |
| An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies | $4.8M | 0 | 768 |
| Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | $4.7M | 0 | 2,206 |
| A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults | $4.5M | 0 | 30 |
| An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzamab and mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer. | $4.1M | 0 | 228 |
| A Phase II Study Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas | $4.0M | 0 | 28 |
| Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | $4.0M | 0 | 663 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Andrew Whiteley | Internal Medicine | Dallas, TX | $1.0M | $0 |
| Dr. Moshe Levy, Md, MD | Medical Oncology | Dallas, TX | $1.0M | $0 |
| Mrs. Shannon Fitzgerald, Crnp, CRNP | Family | Allison Park, PA | $363,327 | $0 |
| Michel Velez, Md, MD | Internal Medicine | Orlando, FL | $193,200 | $0 |
| Timothy Moore, Md, MD | Hospice and Palliative Medicine | Columbus, OH | $164,061 | $0 |
| Dr. Vincent Herrin, Md, MD | Hematology | Jackson, MS | $157,828 | $0 |
| Jenna Mtui, Pnp, PNP | Pediatrics | Denver, CO | $154,929 | $0 |
| Dr. Daniel Landau, Md, MD | Hematology & Oncology | Orlando, FL | $152,764 | $0 |
| Dr. Kevin Rakszawski, M.d, M.D | Hematology & Oncology | Hershey, PA | $146,596 | $0 |
| Dr. Wassim Mchayleh, Md, MD | Hematology & Oncology | Altamonte Springs, FL | $145,848 | $0 |
| M. Donnelly, M.d, M.D | Medical Oncology | Gardner, MA | $137,917 | $0 |
| Hillard Lazarus, Md, MD | Hematology & Oncology | Cleveland, OH | $137,097 | $0 |
| Dr. Ahmed Sawas, M.d, M.D | Hematology & Oncology | New York, NY | $135,910 | $0 |
| Joshua Brody, M.d, M.D | Hematology & Oncology | New York, NY | $133,827 | $0 |
| Andrew Evens, Do, Ms, DO, MS | Hematology | Boston, MA | $131,234 | $0 |
| Maria Theodoulou, Md, MD | Medical Oncology | Albany, NY | $130,717 | $0 |
| Mr. Ruemu Birhiray, Md, MD | Hematology & Oncology | Indianapolis, IN | $122,633 | $0 |
| Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD | Hematology & Oncology | Seattle, WA | $118,001 | $0 |
| Dr. Leonid Shunyakov, Md, MD | Medical Oncology | Bolivar, MO | $113,903 | $0 |
| Dr. Prateek Mendiratta, M.d, M.D | Medical Oncology | Beachwood, OH | $111,576 | $0 |
| Bradley Monk, Md, MD | Gynecologic Oncology | West Palm Beach, FL | $110,842 | $0 |
| Dr. Kit Lu, M.d, M.D | Hematology & Oncology | Harrisburg, PA | $109,333 | $0 |
| Dr. Joyce O'shaughnessy, Md, MD | Medical Oncology | Dallas, TX | $105,434 | $0 |
| Dr. Timothy Pluard, Md, MD | Medical Oncology | Kansas City, MO | $105,327 | $0 |
| Linnea Chap, M.d, M.D | Hematology & Oncology | Beverly Hills, CA | $99,996 | $0 |
About Seagen Inc.
Seagen Inc. has made $512.5M in payments to 15,720 healthcare providers, recorded across 137,462 transactions in the CMS Open Payments database. In 2024, the company paid $52,326. The top product by payment volume is TUKYSA ($196.7M).
Payments were distributed across 164 medical specialties. The top specialty by payment amount is Hematology & Oncology ($5.4M to 3,436 doctors).
Payment categories include: Food & Beverage ($1.9M), Consulting ($5.7M), Research ($491.9M), Travel & Lodging ($1.5M), Royalties ($641,000).
Seagen Inc. is associated with 4 products in the CMS Open Payments database, including TUKYSA, ADCETRIS, and PADCEV.